518 related articles for article (PubMed ID: 26045274)
21. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
[TBL] [Abstract][Full Text] [Related]
22. From DCPD to NTCP: the long journey towards identifying a functional hepatitis B virus receptor.
Li J; Tong S
Clin Mol Hepatol; 2015 Sep; 21(3):193-9. PubMed ID: 26523264
[TBL] [Abstract][Full Text] [Related]
23. Long-term
Lowjaga KAAT; Kirstgen M; Müller SF; Goldmann N; Lehmann F; Glebe D; Geyer J
Am J Physiol Gastrointest Liver Physiol; 2021 Jan; 320(1):G66-G80. PubMed ID: 33174454
[TBL] [Abstract][Full Text] [Related]
24. Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
Li J; Zong L; Sureau C; Barker L; Wands JR; Tong S
J Virol; 2016 Sep; 90(18):8302-13. PubMed ID: 27384660
[TBL] [Abstract][Full Text] [Related]
25. Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.
Lempp FA; Wiedtke E; Qu B; Roques P; Chemin I; Vondran FWR; Le Grand R; Grimm D; Urban S
Hepatology; 2017 Sep; 66(3):703-716. PubMed ID: 28195359
[TBL] [Abstract][Full Text] [Related]
26. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
Blanchet M; Sureau C; Labonté P
Antiviral Res; 2014 Jun; 106():111-5. PubMed ID: 24717262
[TBL] [Abstract][Full Text] [Related]
27. NTCP Oligomerization Occurs Downstream of the NTCP-EGFR Interaction during Hepatitis B Virus Internalization.
Fukano K; Oshima M; Tsukuda S; Aizaki H; Ohki M; Park SY; Wakita T; Wakae K; Watashi K; Muramatsu M
J Virol; 2021 Nov; 95(24):e0093821. PubMed ID: 34613794
[TBL] [Abstract][Full Text] [Related]
28. The p.Ser267Phe variant of sodium taurocholate cotransporting polypeptide (NTCP) supports HBV infection with a low efficiency.
Liu C; Xu G; Gao Z; Zhou Z; Guo G; Li D; Jing Z; Sui J; Li W
Virology; 2018 Sep; 522():168-176. PubMed ID: 30032030
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.
Nio Y; Akahori Y; Okamura H; Watashi K; Wakita T; Hijikata M
Biochem Biophys Res Commun; 2018 Jun; 501(3):820-825. PubMed ID: 29723527
[TBL] [Abstract][Full Text] [Related]
30. Woodchuck sodium taurocholate cotransporting polypeptide supports low-level hepatitis B and D virus entry.
Fu L; Hu H; Liu Y; Jing Z; Li W
Virology; 2017 May; 505():1-11. PubMed ID: 28213271
[TBL] [Abstract][Full Text] [Related]
31. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
[TBL] [Abstract][Full Text] [Related]
32. HBV: Stowaway of NTCP.
Elinger S
Clin Res Hepatol Gastroenterol; 2014 Dec; 38(6):661-3. PubMed ID: 25178832
[TBL] [Abstract][Full Text] [Related]
33. Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication.
Qiao L; Sui J; Luo G
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232184
[TBL] [Abstract][Full Text] [Related]
34. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
[TBL] [Abstract][Full Text] [Related]
35. Interleukin 6 inhibits HBV entry through NTCP down regulation.
Bouezzedine F; Fardel O; Gripon P
Virology; 2015 Jul; 481():34-42. PubMed ID: 25765005
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of hepatitis B virus attachment and entry.
Lempp FA; Urban S
Intervirology; 2014; 57(3-4):151-7. PubMed ID: 25034482
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.
Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Glebe D; Baringhaus KH; Geyer J
Viruses; 2021 Apr; 13(4):. PubMed ID: 33921515
[TBL] [Abstract][Full Text] [Related]
38. Molecular regulation of the hepatic bile acid uptake transporter and HBV entry receptor NTCP.
Appelman MD; Wettengel JM; Protzer U; Oude Elferink RPJ; van de Graaf SFJ
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Aug; 1866(8):158960. PubMed ID: 33932583
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B Virus and Hepatitis D Virus Entry, Species Specificity, and Tissue Tropism.
Watashi K; Wakita T
Cold Spring Harb Perspect Med; 2015 Aug; 5(8):a021378. PubMed ID: 26238794
[TBL] [Abstract][Full Text] [Related]
40. Role of Sodium Taurocholate Cotransporting Polypeptide as a New Reporter and Drug-Screening Platform: Implications for Preventing Hepatitis B Virus Infections.
Wu MR; Huang YY; Hsiao JK
Mol Imaging Biol; 2020 Apr; 22(2):313-323. PubMed ID: 31140111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
